Relez Therapeutics

Relez Therapeutics is a biotechnology company focused on developing innovative therapies for neuropsychiatric and neurological disorders. The company specializes in the discovery and development of next-generation small molecule modulators of the GABA-A receptor, a key inhibitory neurotransmitter system in the brain. Founded by a team of industry veterans from Sage Therapeutics, Relez aims to improve upon existing neuroactive steroid treatments by optimizing pharmacokinetic properties and safety profiles. Their primary therapeutic targets include major depressive disorder and postpartum depression, where there is a significant need for rapid-acting, effective treatments. The company leverages deep expertise in medicinal chemistry and neuroscience to advance its pipeline of novel GABAergic ligands.